(Q36620291)

15 August 2017

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines (English)

1 reference

15 August 2017

1 reference

1 reference

8

G J Peters

1 reference

15 August 2017

C J van Moorsel

1

1 reference

15 August 2017

H M Pinedo

2

1 reference

15 August 2017

G Veerman

3

1 reference

15 August 2017

A M Bergman

4

1 reference

15 August 2017

C M Kuiper

5

1 reference

15 August 2017

J B Vermorken

6

1 reference

15 August 2017

W J van der Vijgh

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 June 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

80

1 reference

15 August 2017

7

1 reference

15 August 2017

981-990

1 reference

Gemcitabine: Future Prospects of Single-Agent and Combination Studies

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Synergistic interaction between cisplatin and gemcitabine in vitro.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Clinical pharmacokinetics of anti-metabolites.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Cisplatin resistance in human cancers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Clinical Pharmacokinetics of Carboplatin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363050

Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity

28 June 2018

1 reference

12 December 2020

Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin

1 reference

12 December 2020

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

12 December 2020

Action of 2',2'-difluorodeoxycytidine on DNA synthesis

1 reference

12 December 2020

Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection

1 reference

12 December 2020

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine

1 reference

12 December 2020

Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin

1 reference

12 December 2020

Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells

1 reference

12 December 2020

Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation

1 reference

12 December 2020

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

Crossref

https://api.crossref.org/works/10.1038/SJ.BJC.6690452

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6690452

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

10362105

1 reference